{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:26:09Z","timestamp":1790375169210,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jacc.2019.08.1024","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T15:41:23Z","timestamp":1571672483000},"page":"2132-2146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia"],"prefix":"10.1016","volume":"74","author":[{"given":"Michael J.","family":"Koren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisle","family":"Langslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.jacc.2019.08.1024_bib1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib2","first-page":"136","article-title":"Repatha (evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jacc.2019.08.1024_bib3","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.08.1024_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.08.1024_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.08.1024_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.08.1024_bib8","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.08.1024_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2019.08.1024_bib10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.08.1024_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over\u00a0\u22651.5 years (from the phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.08.1024_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.08.1024_bib14","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib15","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.08.1024_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2019.08.1024_bib19","first-page":"1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jacc.2019.08.1024_bib20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib22","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.08.1024_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.08.1024_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","article-title":"Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention","volume":"59","author":"Perreault","year":"2005","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719374601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719374601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:57Z","timestamp":1760016297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719374601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0735109719374601"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1024","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}